• +1-646-491-9876
    • +91-20-67278686

    Search

    Melanocyte Protein PMEL-Pipeline Review H1 2017

    Melanocyte Protein PMEL-Pipeline Review H1 2017

    • Report Code ID: RW0001834458
    • Category Pharmaceuticals
    • No. of Pages 61
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Pipeline Review, H1 2017

    Summary

    Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocyte Protein PMEL - Pipeline Review, H1 2017, outlays comprehensive information on the Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Melanocyte protein PMEL also known as premelanosome protein (PMEL) is a protein encoded by the PMEL gene. This protein is involved in generating internal matrix fibers that define the transition from Stage I to Stage II melanosomes. This protein undergoes a complex pattern of posttranslational processing and modification that is essential to the proper functioning of the protein. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 2 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Glioblastoma Multiforme (GBM) , Melanoma and Metastatic Melanoma.

    Furthermore, this report also reviewsalso reviews key players involved in Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL)
    - The report reviews Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Overview
    Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Therapeutics Assessment
    Assessment by Route of Administration
    Assessment by Molecule Type
    Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Companies Involved in Therapeutics Development
    Antigen Express Inc
    ImmunoCellular Therapeutics Ltd
    Scancell Holdings Plc
    Vault Pharma Inc
    Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Drug Profiles
    AE-M vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy to Target gp100 for Melanoma and Non Small Cell Lung Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ICT-107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SCIB-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target GP100, HAGE and TRP2 for Glioblastoma Multiforme - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VPI-121 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Dormant Products
    Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Discontinued Products
    Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Product Development Milestones
    Featured News & Press Releases
    Mar 06, 2017: ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma Trial and Announces Advances in Stem-to-T-Cell Research Program
    Feb 14, 2017: SAVSU Technologies Provides Performance Update on evo Cold Chain 2.0 System in ImmunoCellular Therapeutics Phase 3 Glioblastoma Cell Therapy Clinical Trial
    Jan 03, 2017: Final SCIB1 Phase 1/2 Clinical Study Report completed on schedule
    Nov 21, 2016: ImmunoCellular Therapeutics Reports Updated Immune Monitoring Data from ICT-107 Phase 2 Trial in Newly Diagnosed Glioblastoma at the Society for Neuro-Oncology Annual Meeting 2016
    Aug 02, 2016: ImmunoCellular Therapeutics Provides Update On ICT-107 Master Services Agreement With Aptiv Solutions
    Jul 25, 2016: ImmunoCellular Therapeutics Provides Update on Lead Cancer Immunotherapy ICT-107
    Jul 21, 2016: Scancell Holdings Announces Leading DNA plasmid manufacturer Eurogentec appointed to manufacture new SCIB1 material
    Jul 06, 2016: SCIB1 continues to deliver compelling survival data in melanoma
    Jun 17, 2016: SCIB1 Drug Product Supply
    Jun 07, 2016: ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma
    Jun 02, 2016: ImmunoBody vaccine to be developed for the treatment of glioblastoma multiforme
    May 19, 2016: BioLife Solutions and MNX Global Logistics Partner to Support ImmunoCellular Therapeutics with Cold Chain Logistics in ICT-107 Phase 3 Clinical Trial in Glioblastoma
    May 06, 2016: ImmunoCellular Therapeutics Receives Regulatory Approval in Canada, the UK and the Netherlands to Initiate ICT-107 Phase 3 Trial in Newly Diagnosed Glioblastoma
    Mar 23, 2016: Scancell's SCIB1 ImmunoBody cancer vaccine being presented at the World Vaccine Congress
    Mar 03, 2016: Cryoport Supports ImmunoCellular Therapeutics' 120-Site Phase III Clinical Trial With Cold Chain Logistics
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Antigen Express Inc, H1 2017
    Pipeline by ImmunoCellular Therapeutics Ltd, H1 2017
    Pipeline by Scancell Holdings Plc, H1 2017
    Pipeline by Vault Pharma Inc, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Antigen Express Inc
    ImmunoCellular Therapeutics Ltd
    Scancell Holdings Plc
    Vault Pharma Inc

    Request for Sample

    Report Url https://www.reportsweb.com//melanocyte-protein-pmel-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//melanocyte-protein-pmel-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//melanocyte-protein-pmel-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments